ImmunityBio, Inc. (IBRX)

9.15 +0.18 (+2.01%) At close: 04:00PM EDT

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
844 696 5235
https://immunitybio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 628

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	865.34k	N/A	1953
Mr. Richard Gerald Adcock	President, CEO & Director	1.16M	N/A	1969
Mr. David C. Sachs	Chief Financial Officer	824.62k	N/A	1978
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director	N/A	N/A	1965
Dr. Leonard S. Sender M.D.	Chief Operating Officer	N/A	N/A	N/A
Ms. Regan J. Lauer	Chief Accounting Officer	N/A	N/A	1970
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer	N/A	N/A	1967
Mr. Jason R. Liljestrom	General Counsel & Corporate Secretary	N/A	N/A	1983
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	N/A	N/A	N/A
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Corporate governance

ImmunityBio, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.